Primary cutaneous melanoma: a complication of infliximab treatment?
Khan
I
I
Rahman
L
L
McKenna
D B
DB
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006258:Head and Neck Neoplasms / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D008297:Male; D008545:Melanoma / Q000139:chemically induced* / Q000473:pathology; D012535:Scalp / Q000473:pathology*; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab